Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 7/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | PKLR | P30613 | 1/20 | 0.34 |
| ▸ | CTSD | P07339 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6762034 | 0.87 | F2 (0.41) | LMNAALDH1A1F2TP53 | |
| SCHEMBL6574056 | 0.79 | RORC (0.45) | IDH1RORCLMNAALDH1A1IDO1 | |
| SCHEMBL6766536 | 0.78 | HDAC1 (0.52) | RORCLMNA | |
| SCHEMBL6571783 | 0.78 | LMNA (0.51) | IDH1RORCLMNAALDH1A1IDO1 | |
| SCHEMBL6574032 | 0.77 | HIF1A (0.43) | IDH1RORCLMNAALDH1A1 | |
| SCHEMBL6574325 | 0.76 | LMNA (0.44) | IDH1RORCLMNAALDH1A1TP53 | |
| SCHEMBL6572882 | 0.73 | MEN1 (0.52) | ALDH1A1TP53PKMPKLR | |
| SCHEMBL6765129 | 0.73 | MGAT2 (0.56) | RORCLMNAALDH1A1 | |
| SCHEMBL6764580 | 0.71 | HDAC1 (0.45) | RORCLMNAPARP1IDO1 | |
| SCHEMBL6762133 | 0.71 | POLB (0.53) | RORCLMNAALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040248897-A1 | Substituted N-acylaniline derivatives, the preparation thereof, and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-12-09 | — | — | US | disclosed |
| EP-1414790-A1 | SUBSTITUTED N-ACYL ANILINE DERIVATIVES, PRODUCTION AND USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003000653-A1 | SUBSTITUTED N-ACYL ANILINE DERIVATIVES, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG (DE) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248897-A1 | Substituted N-acylaniline derivatives, the preparation thereof, and their use as pharmaceutical compositions | NAT1, CYP3A5, CYP3A7 | IDH1 602/4885RORC 1596/4885LMNA 1447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.